Enrollment Complete in Study Evaluating the Performance of the Ringer™ Perfusion Balloon Catheter in Patients Undergoing Percutaneous Coronary Interventions
WAYNE, Pa., July 19, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in the prospective multicenter RingerTM PTCA study. RingerTM PTCA is one of two clinical studies evaluating the performance of the novel RingerTM Perfusion Balloon Catheter. The RingerTM PTCA study enrolled patients at seven leading complex PCI centers in the US and Canada. Led by Principal Investigator Kathleen Kearney M.D., University of Washington, the study employed the RingerTM Device in selected coronary intervention patients who could benefit from continued perfusion during coronary balloon inflations.